Case Studies

WEP Clinical is committed to supporting companies in the pharmaceutical industry to help make much-needed medicines available to patients, physicians, hospitals and R&D centers.

EAP
PA-NPP
Market Access
Nursing

Expanded Access

Check out our case studies to the right, or click below to learn more about our Expanded Access services.

Learn More

HELPING A SPONSOR COLLECT DATA IN AN EXPANDED ACCESS PROGRAM TO SUPPORT CLINICAL TRIAL DATA

Therapeutic Area: Oncology Clinical Trial Phase: Phase 2

HOW STRONG PROJECT MANAGEMENT DELIVERED A SUCCESSFUL CELL THERAPY EAP

Therapeutic Area: Cell therapy Clinical Trial Phase: Phase 2

HELPING A SPONSOR PROVIDE ACCESS TO INVESTIGATIONAL DRUG OUTSIDE OF CLINICAL TRIAL

Condition: Rare, progressive autoimmune condition Clinical Trial Phase: Completed Phase 3

HELPING A SPONSOR SCALE UP AN EAP TO FULFILL INCREASE IN DEMAND FOR PROMISING ONCOLOGY PRODUCT

Therapeutic Area: Oncology Clinical Trial Phase: Phase 3

USING EXPANDED ACCESS AS AN ALTERNATIVE TO AN OPEN LABEL EXTENSION (OLE) STUDY

Condition: Rare Gastrointestinal Tumors Clinical Trial Phase: Phase 2

HELPING A SPONSOR RESCUE AN EXISTING EAP FROM ANOTHER VENDOR

Condition: Debilitating neurological disorder Clinical Trial Phase: Completed Phase 3

RAPIDLY SCALING AN EAP TO FULFIL UNMET CLINICAL NEED FOR PATIENTS WITH LIFE-THREATENING SEIZURES

Therapeutic Area: Rare Disease Clinical Trial Phase: Completed Phase 3

EXPERTLY NAVIGATING REGULATORY COMPLEXITIES DURING AN EXPANDED ACCESS PROGRAM

Therapeutic Area: Rare Disease Clinical Trial Phase: Phase 3

Post-Approval Named Patient

Check out our case studies to the right, or click below to learn more about our PA-NPP services.

Learn More

Providing a Paid-For Post-Approval Named Patient Program

Condition: Rare autoimmune disorder Approved in: US

USING A PA-NPP TO CREATE ACCESS FOR A CANADIAN-APPROVED PRODUCT IN EUROPE

Condition: Genetic metabolic disorder Approved in: Canada

SUPPORTING A MEDICINE THROUGHOUT THE DEVELOPMENT JOURNEY

Condition: Rare autoimmune disease Approved in: US and Europe

PROVIDING SITE TRAINING AS PART OF A PA-NPP FOR A SPECIALIZED PRODUCT

Condition: Pediatric cancer Approved in: US

Market Access

Check out our case studies to the right, or click below to learn more about our Market Access services.

Learn More

SUPPORTING A MEDICINE THROUGHOUT THE DEVELOPMENT JOURNEY

Condition: Rare autoimmune disease Approved in: US and Europe

PROVIDING DRUG IN FRANCE THROUGH REVISED LEGISLATION FOR AAC COMPASSIONATE USE ACCESS

Condition: Serious, debilitating condition Approved in: US

PROVIDING EU5 MARKET ACCESS STRATEGY AND REIMBURSEMENT SUPPORT

Treatment Type: Emergency medicine Approved in: US

Nursing Solutions

To learn more about our nursing services, click below to visit the Wren Healthcare website.

Learn More

HOW WEP's COUNTRY COORDINATOR TEAM HELPS SUCCESSFULLY DELIVER AN ONGOING MOBILE NURSING SOLUTION

Condition: Rare Neurodegenerative Disease Clinical Trial Phase: Phase 3

UTILIZING A MOBILE NURSING SOLUTION TO HELP ENHANCE PATIENT RECRUITMENT IN A PEDIATRIC CLINICAL TRIAL

Condition: Rare Genetic Disease Clinical Trial Phase: Phase 3

PROVIDING CLINICAL HOMECARE NURSING SERVICES FOR VACCINE STUDY IN THE UK

Condition: Infectious Disease Clinical Trial Phase: Phase 3

SUPPORTING A SPONSOR WITH HOME HEALTHCARE SERVICES FOR AN ORAL CANCER TREATMENT CLINICAL TRIAL

Condition: Solid Tumors Clinical Trial Phase: Phase 2

PROVIDING SITE TRAINING AS PART OF A PA-NPP FOR A SPECIALIZED PRODUCT

Condition: Pediatric cancer Approved in: US

NEED MORE INFORMATION?

Contact Us